NASDAQ : CLPT
ClearPoint Neuro, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 10.69 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 342.63M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 342.02M |
| Enterprise Value | 369.53M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 32.05M |
| Shares Outstanding | 32.05M |
| Shares Change (YoY) | +6.75% |
| Shares Change (QoQ) | +2.71% |
| Owned by Insiders (%) | 5.76% |
| Owned by Institutions (%) | 41.75% |
| Float | 27.83M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.52 |
| Forward PS | 6.38 |
| PB Ratio | 12.54 |
| P/TBV Ratio | 46.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 8.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.76 |
| Quick Ratio | 5.60 |
| Debt / Equity | 2.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.69 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -167.52% |
| Return on Assets (ROA) | -21.88% |
| Return on Invested Capital (ROIC) | -24.82% |
| Return on Capital Employed (ROCE) | -29.46% |
| Weighted Average Cost of Capital (WACC) | 10.34% |
| Revenue Per Employee | $264,494 |
| Profits Per Employee | -$210,087 |
| Employee Count | 172 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.15 |
Taxes
| Measure | Value |
|---|
| Income Tax | -30,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -55.74% |
| 50-Day Moving Average | 12.51 |
| 200-Day Moving Average | 12.96 |
| Relative Strength Index (RSI) | 48.93 |
| Average Volume (20 Days) | 683,912 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.63M |
| Short Previous Month | 4.76M |
| Short % of Shares Out | 14.44% |
| Short % of Float | 16.63% |
| Short Ratio (days to cover) | 6.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 45.49M |
| Gross Profit | 27.93M |
| Operating Income | -30.30M |
| Pretax Income | -36.17M |
| Net Income | -36.14M |
| EBITDA | -29.02M |
| EBIT | -30.30M |
| Loss Per Share | -$1.21 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 46.18M |
| Total Debt | 73.70M |
| Net Cash | -27.52M |
| Net Cash Per Share | -$0.86 |
| Equity (Book Value) | 27.27M |
| Book Value Per Share | 0.85 |
| Working Capital | 56.85M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -32.17M |
| Capital Expenditures | -1.05M |
| Depreciation & Amortization | 1.28M |
| Net Borrowing | 19.43M |
| Free Cash Flow | -33.22M |
| FCF Per Share | -$1.04 |
Margins
| Measure | Value |
|---|
| Gross Margin | 61.39% |
| Operating Margin | -66.60% |
| Pretax Margin | -79.50% |
| Profit Margin | -79.43% |
| EBITDA Margin | -63.80% |
| EBIT Margin | -66.60% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.75% |
| Shareholder Yield | -6.75% |
| Earnings Yield | -11.33% |
| FCF Yield | -9.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $21.50 |
| Price Target Difference | 101.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 21.31% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 27, 2016 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.14 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |